13 May, 2017
DENTSPLY SIRONA Inc.'s P/E ratio now stands at 32.91, while the P/S ratio is at 4.04 and the potential growth rate of earnings per share this year is at 10.10%.
Large investors have recently added to or reduced their stakes in the stock. Northwest Wealth Management LLC raised its position in shares of DENTSPLY SIRONA by 1.4% in the first quarter. Finally, Focused Wealth Management Inc boosted its stake in DENTSPLY SIRONA by 179.2% in the fourth quarter. Finally, Bessemer Group Inc. increased its stake in shares of DENTSPLY SIRONA by 0.4% in the fourth quarter. Schroder Investment Management Group now owns 1,541,053 shares of the medical instruments supplier's stock valued at $96,547,000 after buying an additional 141,346 shares during the period. JNBA Financial Advisors boosted its stake in DENTSPLY SIRONA by 803.0% in the fourth quarter.
22nd Century Group, Inc. Glenview Trust Co acquired a new stake in DENTSPLY SIRONA during the first quarter valued at approximately $451,000. Price T Rowe Associates Inc. World Asset Management Inc now owns 23,252 shares of the medical instruments supplier's stock valued at $1,382,000 after buying an additional 244 shares during the period.
A number of hedge funds have recently made changes to their positions in XRAY.
DENTSPLY SIRONA (NASDAQ:XRAY) opened at 62.52 on Thursday. These shares are worth $3,212,594 and were traded at $63.49 each. In a transaction dated March 09, 2017, the shares were put up for sale at an average price of $62.84, raking in a sum of $1,508,160. A beta of less than 1 means that the security will be less volatile than the market.
At the moment 15 analysts are watching DENTSPLY SIRONA Inc. DENTSPLY INTERNATIONAL INC. (XRAY) has received mean Analyst rating of 2.13 from polled analysts at Reuters. The medical instruments supplier reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The company had revenue of $900.50 million for the quarter, compared to analyst estimates of $916.55 million. DENTSPLY SIRONA had a return on equity of 8.04% and a net margin of 11.15%.
Pioneer Natural Resources Company (PXD) have shown a high EPS growth of -25.80% in the last 5 years and has earnings decline of -87.60% yoy.
Earnings estimate: "14" Analysts are saying that the company to report next quarterly earnings of $0.83 per share for period Quarter Ending_Sep-17. Northcoast Research also issued estimates for DENTSPLY SIRONA's Q3 2017 earnings at $0.79 EPS, FY2017 earnings at $2.85 EPS, Q2 2018 earnings at $0.82 EPS and Q3 2018 earnings at $0.89 EPS. Shareholders of record on Friday, March 31st were paid a $0.0875 dividend.
On 12/15/2016 announced a quarterly dividend of $0.08 0.52% with an ex dividend date of 12/28/2016 which will be payable on 12/30/2016. The stock's Dividend Yield stands at 0.53%. DENTSPLY SIRONA's dividend payout ratio (DPR) is now 15.98%.
"TRADEMARK VIOLATION WARNING: "[[title]]" was first reported by [[site]] and is the sole property of of [[site]]. If you are accessing this report on another site, it was stolen and reposted in violation of worldwide copyright & trademark law.
The simple 20 day moving average for DENTSPLY SIRONA Inc.is 2.90% and the simple 200-day moving average is at 7.67%. Over the last three months, the shares of the company have changed 14.43% and performed 10.17% over the last six months.
FT reports, The 12 analysts offering 12 month price targets for DENTSPLY SIRONA Inc have a median target of 66.50, with a high estimate of 76.00 and a low estimate of 60.00. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.77 average brokerage recommendation.
In other news, CEO James G. Mosch sold 50,600 shares of the firm's stock in a transaction on Monday, April 24th.
On 4/7/2017 Christopher T Clark, CEO, sold 89,700 with an average share price of $62.67 per share and the total transaction amounting to $5,621,499.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Following the transaction, the insider now directly owns 142,121 shares of the company's stock, valued at approximately $9,119,904.57. The disclosure for this sale can be found here.
Institutional investors now hold around $14.56 billion or 0% in XRAY stock.
What Analysts think about DENTSPLY SIRONA Inc. Additionally, its consumable medical device products are used for urological and surgical applications. It operates through two segments: Dental and Healthcare Consumables, and Technologies.